NBIO
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q2 | -0.00 | $0 | — |
| 2024 Q1 | -0.00 | $0 | -$324,729 |
| 2024 Q4 | -0.00 | $3 | -$351,735 |
| 2023 Q3 | -0.00 | $0 | -$330,113 |
| 2023 Q2 | -0.01 | $0 | -$341,512 |
| 2023 Q1 | -0.00 | $0 | -$162,706 |
| 2023 Q4 | -0.00 | $0 | -$386,578 |
| 2022 Q3 | -0.01 | $0 | -$623,148 |